Show simple item record

dc.contributor.authorPearson, James A
dc.contributor.authorMcKinney, Eoin F
dc.contributor.authorWalker, Lucy SK
dc.date.accessioned2022-03-19T02:06:45Z
dc.date.available2022-03-19T02:06:45Z
dc.date.issued2021-01
dc.identifier.issn2732-4303
dc.identifier.other35156097
dc.identifier.otherPMC8826223
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/335214
dc.description.abstractType 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for people with T1D, preventing this from being a fatal condition. As we celebrate the centenary of this milestone, therapeutic options for T1D are once more at a turning point. Years of effort directed at developing immunotherapies are finally starting to pay off, with signs of progress in new onset and even preventative settings. Here, we review a selection of immunotherapies that have shown promise in preserving β cell function and highlight future considerations for immunotherapy in the T1D setting.
dc.languageeng
dc.publisherOxford University Press (OUP)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceessn: 2732-4303
dc.sourcenlmid: 101776979
dc.subjectHuman
dc.subjectImmunotherapy
dc.subjecttype 1 diabetes
dc.subjectNod Mouse
dc.title100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes.
dc.typeArticle
dc.date.updated2022-03-19T02:06:44Z
prism.issueIdentifier1
prism.publicationNameImmunother Adv
prism.volume1
dc.identifier.doi10.17863/CAM.82644
dcterms.dateAccepted2021-11-20
rioxxterms.versionofrecord10.1093/immadv/ltab024
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidPearson, James A [0000-0002-2867-2269]
dc.identifier.eissn2732-4303
pubs.funder-project-idMedical Research Council (MR/S009140/1, MR/N001435/1)
pubs.funder-project-idWellcome Trust (220772/Z/20/Z)
pubs.funder-project-idDiabetes UK (20/0006172)
cam.issuedOnline2021-11-24


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International